Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 202

Sort by

Sort Order Select

Journal Articles

Ligand Based CAR T-Cell Targeting BAFF Receptors Asa Novel Therapy for B Cell Malignancies

Reshmi Parameswaran, PhD, Derek Wong, Keman Zhang, Abhishek Asthana, PhD, Marcos de Lima, MD, Paolo F Caimi, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-141009

Published: 2020

Journal Articles

Impact of Daratumumab on Stem Cell Collection, Graft Composition and Engraftment Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant

Shivaprasad Manjappa, MDMBBS, Robert Fox, Jane Reese, Amin Firoozamand, MD, Hannah Schmikla, RN, Savannah Nall, RN, Merle Kolk, Paolo F Caimi, MD, James J. Driscoll, MD PhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2020) 136 (Supplement 1): 35–37.

https://doi.org/10.1182/blood-2020-142115

Published: 2020

Journal Articles

Prognostic Impact of a Modified European LeukemiaNet (ELN) Genetic Risk Stratification in Predicting Outcomes for Adults with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCT). a Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis for the CIBMTR Acute Leukemia Writing Committee

Blood (2020) 136 (Supplement 1): 27–29.

https://doi.org/10.1182/blood-2020-137589

Published: 2020

Journal Articles

Patient Selection Bias Limits the Real World Efficacy of Randomized Clinical Trials in Multiple Myeloma

Augusta Eduafo, DO, Leland Metheny, III, MD, James Driscoll, Benjamin K. Tomlinson, MD, Kirsten M Boughan, DO, Molly M Gallogly, MDPhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-139856

Published: 2020

Journal Articles

CAR-T Therapy for Lymphoma with Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome without Excessive Neurologic Toxicity

Paolo F Caimi, MD, Ashish Sharma, Patricio Rojas, MD, Seema Patel, PharmD, Jane Reese, Folashade Otegbeye, MBBChir,MPH, Andrew Worden, Michael Kadan, Michael Maschan, MD PhD, Rimas J Orentas, PhD, Boro Dropulic, PhDMBA, Rafick Sekaly, Marcos de Lima, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-143114

Published: 2020

Journal Articles

Low Dose Daily Corticosteroid Tapering Regimen Allows Highly Effective and Practical Desensitization for Multiple Myeloma Patients with Skin Rash after Immunomodulatory Drugs

Amin Firoozmand, MD, Naveed Ali, MD, Nausheen Ahmed, MD, Pingfu Fu, Shufen Cao, George Brown, Hannah Schmikla, RN, James J. Driscoll, MD PhD, Timothy O'Brien, Paolo Caimi, MD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-140800

Published: 2020

Journal Articles

Health Care Burden of Monogammopathy of Renal Significance

Jeries Kort, MD, Paolo F Caimi, MD, Pingfu Fu, PhD, Shufen Cao, James Driscoll, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2020) 136 (Supplement 1): 34–36.

https://doi.org/10.1182/blood-2020-139740

Published: 2020

Journal Articles

Whole-Exome Sequencing Identifies a Somatic Cell Mutation Signature That Predicts Relapse Risk and Survival Probability in Multiple Myeloma

Ehsan Malek, MD, E. Ricky Chan, PhD, Daniel Qu, Jane Reese, Robert Fox, Byung-Gyu Kim, PhD DVM, Paolo F Caimi, MD, Marcos de Lima, MD, James J. Driscoll, MD PhD

Blood (2020) 136 (Supplement 1): 5.

https://doi.org/10.1182/blood-2020-142791

Published: 2020

Journal Articles

Final Results of a Dual-Institution Phase I Clinical Trial of Targeted Marrow Irradiation (TMI) Intensification of Reduced-Intensity Fludarabine/Busulfan (Flu/Bu) Conditioning for Allogeneic Hematopoietic Cell Transplantation for Medically Frail Patients with High-Risk Hematological Malignancies

Naveed Ali, MD, Ana Carolina Pires de Rezende, MD, Folashade Otegbeye, MBBChir,MPH, Mariana Nassif Kerbauy, MD, Brenda W. Cooper, MD, David Mansur, MD, Gisele Pereira, PhD, Roberto Sakuraba, MD, Benjamin K. Tomlinson, MD, Kirsten M Boughan, DO, Cinthya Correa Silva, MD, Leland Metheny, III, MD, Andreza Feitosa Ribeiro, MD, Molly M Gallogly, MDPhD, Ehsan Malek, MD, EDuardo Weltman, MD, Marcos de Lima, MD, Nelson Hamerschlak, MD PhD, Paolo F Caimi, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142197

Published: 2020

Journal Articles

Risk of Secondary Malignancy in CLL Patients Treated with Novel Targeted Agents

Anna Eversman, Shufen Cao, Kirsten M Boughan, DO, Molly M Gallogly, MDPhD, Ehsan Malek, MD, Leland Metheny, III, MD, Timothy E. O'Brien, MD, Folashade Otegbeye, MBBChir,MPH, Brenda W. Cooper, MD, Pingfu Fu, Marcos de Lima, MD, Paolo F Caimi, MD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-140042

Published: 2020

Journal Articles

Analyzing Risk of Infection with Anti-CD38 Monoclonal Antibody Therapy for Patients with Multiple Myeloma

Augustine Hong, MD, Augusta Eduafo, DO, Hannah Schmikla, RN, George Brown, Gayathri Ravi, MD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2020) 136 (Supplement 1): 49.

https://doi.org/10.1182/blood-2020-140544

Published: 2020

Journal Articles

Development of a Machine Learning Algorithm for Rapid, Point-of-Care Prediction of Serum Monoclonal Proteins in Multiple Myeloma

Ehsan Malek, MD, Jeries Kort, MD, Gi-Ming Wang, PhD, Paolo F Caimi, MD, Kirsten M Boughan, DO, Stanton L. Gerson, MD, Brenda W. Cooper, MD, Molly M Gallogly, MDPhD, Benjamin K. Tomlinson, MD, Marcos de Lima, MD, Curtis Tatsuoka, PhD, James Driscoll

Blood (2020) 136 (Supplement 1): 13–15.

https://doi.org/10.1182/blood-2020-139733

Published: 2020

Journal Articles

Comparison of Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide to Matched-Sibling, Matched-Unrelated, Mismatched-Unrelated, and Umbilical Cord Blood Donor Transplantation in Adults with Acute Lymphoblastic Leukemia: A CIBMTR Study

Matthew J. Wieduwilt, MD PhD, Leland Metheny, III, MD, Mei-Jie Zhang, PhD, Hai-Lin Wang, MPH, Noel Estrada-Merly, MS, Marcos de Lima, MD, Mark Litzow, MD, Partow Kebriaei, MD, Chris S. Hourigan, MDPhD, Daniel J. Weisdorf, MD, Wael Saber, MD MS

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-137186

Published: 2020

Journal Articles

Presence of Chip-Mutated Autologous Hematopoietic Cells in Mobilized Peripheral Blood Products Is Associated with Shorter Progression-Free Survival after Autologous Transplants for Multiple Myeloma

Ehsan Malek, MD, Petra Martin, Paolo F Caimi, MD, Benjamin K. Tomlinson, MD, Michael Caldwell, Gayathri Ravi, MD, Sowjanya Vuyyala, MD, Hannah Schmikla, RN, Robert Fox, Marcos de Lima, MD, Navid Sadri, MD, James Driscoll, MD PhD

Blood (2019) 134 (Supplement_1): 515.

https://doi.org/10.1182/blood-2019-127335

Published: 2019

Journal Articles

Stem Cell Transplant Minimizes Insurance Coverage-Driven Outcomes Disparities for Multiple Myeloma Patients

Gayathri Ravi, MD, Kamal Chamoun, MD, Kirsten M Boughan, DO, Shufen Cao, Pingfu Fu, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2019) 134 (Supplement_1): 424.

https://doi.org/10.1182/blood-2019-126131

Published: 2019

Journal Articles

Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR

Matthew J. Wieduwilt, MD PhD, Wendy Stock, MD, Anjali S. Advani, MD, Selina M. Luger, MD FRCPC, Richard A. Larson, MD, Martin S. Tallman, MD, Frederick R. Appelbaum, MD, Mei-Jie Zhang, Khalid Bo-Subait, Brenda M. Sandmaier, MD, Marcos de Lima, MD, Partow Kebriaei, MD, Mark Litzow, MD, Wael Saber, MD MS, Daniel J. Weisdorf, MD

Blood (2019) 134 (Supplement_1): 261.

https://doi.org/10.1182/blood-2019-128560

Published: 2019

Journal Articles

The Prognostic Factors for Early Fatal Outcome in Patients with Multiple Myeloma

Sowjanya Vuyyala, MD, Kamal Chamoun, MD, Pingfu Fu, Shufen Cao, Molly M Gallogly, MD PhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2019) 134 (Supplement_1): 270.

https://doi.org/10.1182/blood-2019-126156

Published: 2019

Journal Articles

Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT)

Mary-Elizabeth M. Percival, MD, Hai-Lin Wang, MPH, Mei-Jie Zhang, PhD, Elihu H. Estey, MD, Mark Litzow, MD, Partow Kebriaei, MD, Marcos de Lima, MD, Wael Saber, MD MS, Daniel J. Weisdorf, MD, Brenda M Sandmaier, MD

Blood (2019) 134 (Supplement_1): 4585.

https://doi.org/10.1182/blood-2019-123510

Published: 2019

Journal Articles

A Phase I Trial of Venetoclax in Combination with BEAM Conditioning Chemotherapy (V-BEAM) with Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma

Allison M. Winter, MD, Kirsten M Boughan, DO, Jack Khouri, MD, Paolo Caimi, MD, Faiz Anwer, MD, Brenda Cooper, MD, Deepa Jagadeesh, MDMPH, Robert M. Dean, MD, Aaron T. Gerds, MD MS, Ronald Sobecks, MD, Brad Pohlman, MD, Matt Kalaycio, MD, Betty K. Hamilton, MD, Marcos de Lima, MD, Navneet S. Majhail, MD MS, Brian T. Hill, MD

Blood (2019) 134 (Supplement_1): 5705.

https://doi.org/10.1182/blood-2019-124602

Published: 2019

Journal Articles

Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas

Blood (2019) 134 (Supplement_1): 4074.

https://doi.org/10.1182/blood-2019-131300

Published: 2019

NARROW

Ligand Based CAR T-Cell Targeting BAFF Receptors Asa Novel Therapy for B Cell Malignancies

Impact of Daratumumab on Stem Cell Collection, Graft Composition and Engraftment Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant

Patient Selection Bias Limits the Real World Efficacy of Randomized Clinical Trials in Multiple Myeloma

CAR-T Therapy for Lymphoma with Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome without Excessive Neurologic Toxicity

Low Dose Daily Corticosteroid Tapering Regimen Allows Highly Effective and Practical Desensitization for Multiple Myeloma Patients with Skin Rash after Immunomodulatory Drugs

Health Care Burden of Monogammopathy of Renal Significance

Whole-Exome Sequencing Identifies a Somatic Cell Mutation Signature That Predicts Relapse Risk and Survival Probability in Multiple Myeloma

Final Results of a Dual-Institution Phase I Clinical Trial of Targeted Marrow Irradiation (TMI) Intensification of Reduced-Intensity Fludarabine/Busulfan (Flu/Bu) Conditioning for Allogeneic Hematopoietic Cell Transplantation for Medically Frail Patients with High-Risk Hematological Malignancies

Risk of Secondary Malignancy in CLL Patients Treated with Novel Targeted Agents

Analyzing Risk of Infection with Anti-CD38 Monoclonal Antibody Therapy for Patients with Multiple Myeloma

Development of a Machine Learning Algorithm for Rapid, Point-of-Care Prediction of Serum Monoclonal Proteins in Multiple Myeloma

Comparison of Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide to Matched-Sibling, Matched-Unrelated, Mismatched-Unrelated, and Umbilical Cord Blood Donor Transplantation in Adults with Acute Lymphoblastic Leukemia: A CIBMTR Study

Presence of Chip-Mutated Autologous Hematopoietic Cells in Mobilized Peripheral Blood Products Is Associated with Shorter Progression-Free Survival after Autologous Transplants for Multiple Myeloma

Stem Cell Transplant Minimizes Insurance Coverage-Driven Outcomes Disparities for Multiple Myeloma Patients

The Prognostic Factors for Early Fatal Outcome in Patients with Multiple Myeloma

Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT)

A Phase I Trial of Venetoclax in Combination with BEAM Conditioning Chemotherapy (V-BEAM) with Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma

Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only